Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated) ; volume:9 ; number:5 ; day:27 ; month:7 ; year:2005 ; pages:1-6 ; date:10.2005
Critical care ; 9, Heft 5 (27.7.2005), 1-6, 10.2005
- Creator
-
Levy, Howard
- Contributor
-
Laterre, Pierre-François
Bates, Becky
Qualy, Rebecca L.
SpringerLink (Online service)
- DOI
-
10.1186/cc3778
- URN
-
urn:nbn:de:1111-201608087578
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Levy, Howard
- Laterre, Pierre-François
- Bates, Becky
- Qualy, Rebecca L.
- SpringerLink (Online service)
Other Objects (12)
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Physiological-dose steroid therapy in sepsis [ISRCTN36253388]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Physiological-dose steroid therapy in sepsis [ISRCTN36253388]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Physiological-dose steroid therapy in sepsis [ISRCTN36253388]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C